|
9. Discontinued Operations
The components of loss from discontinued operations as reported in our condensed statements of operations and comprehensive loss were as follows:
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Six Months Ended |
|
|
June 30, 2020 |
|
June 30, 2020 |
|
|
|
(In thousands, except per share data) |
Revenue: |
|
|
|
|
|
|
Product revenue |
|
$ |
76 |
|
$ |
286 |
|
|
|
|
|
|
|
Costs and expenses: |
|
|
|
|
|
|
Cost of goods sold |
|
|
228 |
|
|
399 |
Research and development |
|
|
363 |
|
|
828 |
Selling, general and administrative |
|
|
2,251 |
|
|
4,077 |
Total costs and expenses |
|
|
2,842 |
|
|
5,304 |
Loss from discontinued operations |
|
|
(2,766) |
|
|
(5,018) |
Other expense, net |
|
|
— |
|
|
— |
Net loss from discontinued operations |
|
$ |
(2,766) |
|
$ |
(5,018) |
Basic and diluted net loss per common share from discontinued operations |
|
$ |
(0.87) |
|
$ |
(1.70) |
Weighted average shares used in computing basic and diluted net loss per common share |
|
|
3,165 |
|
|
2,960 |
The following table presents information related to assets and liabilities reported as discontinued operations in our condensed balance sheets:
|
|
|
|
|
|
|
|
|
June 30, |
|
December 31, |
|
|
2021 |
|
2020 |
(In thousands) |
|
|
|
|
|
|
Prepaid expenses and other current assets |
|
$ |
70 |
|
$ |
181 |
Discontinued operations – current assets |
|
$ |
70 |
|
$ |
181 |
|
|
|
|
|
|
|
Accounts payable |
|
$ |
1,249 |
|
$ |
1,515 |
Accrued clinical trials expenses |
|
|
25 |
|
|
80 |
Accrued sales allowances |
|
|
— |
|
|
61 |
Other accrued liabilities |
|
|
353 |
|
|
304 |
Discontinued operations – current liabilities |
|
$ |
1,627 |
|
$ |
1,960 |
During the three and six months ended June 30, 2020 we recognized non-cash stock-based compensation expenses of approximately $77,000 and $101,000, respectively, which is included in discontinued operations.
|